CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference
July 11 2014 - 9:00AM
Business Wire
Company’s LEAPS vaccine customized to create
next-generation Rheumatoid Arthritis therapy
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage
oncology company, announced today that Daniel Zimmerman, Ph.D., its
Senior Vice President of Research, Cellular Immunology, delivered a
scientific presentation at the 12th Vaccines Research &
Development: All Things Considered Conference in Boston,
Massachusetts held on July 9-11, 2014.
The presentation entitled “The next generation of Rheumatoid
Arthritis therapies: What has been learned from therapeutic
vaccines for models of Rheumatoid Arthritis. Is IL-17 the real key
to new therapies?” discussed the potential role CEL-SCI’s LEAPS
vaccines might have on the future treatment of Rheumatoid
Arthritis. The presentation centered on the theory that using LEAPS
vaccines to treat a complex disease like Rheumatoid Arthritis can
be beneficial because CEL-SCI’s vaccine can be synthesized to
stimulate the appropriate immune response to treat the disease
based on its immunodominant cytokine phenotype, which can be
predetermined before treatment. The ability to customize the LEAPS
treatment in this way offers clear benefits, as compared to using
one therapeutic approach such as disease-modifying antirheumatic
drugs (DMARDs) that are used today but are not universally
applicable across all rheumatoid arthritis patients. The Company
presented data which showed that LEAPS vaccines act at an earlier
point in the progression of Rheumatoid Arthritis than any other
therapy and with more specificity.
According to a survey conducted by Decision Resources,
rheumatologists believe there is a high unmet need for Rheumatoid
Arthritis therapies which induce remission in a greater percentage
of Rheumatoid Arthritis patients than currently available agents.
The world rheumatoid arthritis drug market will generate revenues
of $38.5 billion in 2017, according to Visiongain.
The data presented included results from studies conducted at
Rush University Medical Center in Chicago, Illinois in the
laboratories of Tibor Glant, MD, Ph.D., The Jorge O. Galante
Professor of Orthopedic Surgery; Katalin Mickecz, MD, Ph.D.
Professor of Orthopedic Surgery & Biochemistry; and Allison
Finnegan, Ph.D. Professor of Medicine. The presentation also drew
on work published from others in related autoimmune conditions
conducted in animal models and human studies that tested various
treatments that are approved or still under investigation. These
data supported CEL-SCI’s theory that vaccine therapies are more
disease specific and act upstream, which are considered advantages,
compared to current therapies.
“We have now shown and believe that LEAPS therapies that are
tailored to either Th1 or Th17 in Rheumatoid Arthritis models
should produce better results than therapies currently on the
market, and we expect these findings would be similar in other
models and human diseases including multiple sclerosis, uveitis and
other autoimmune conditions. We believe that this helps explain why
other therapies that are for Th1 signature conditions may not work
with Th17 based approach and vice versa. As opposed to current
therapies available or in development, LEAPS vaccines target the
immune response well before the production of the signature
cytokines and not after the cytokines have been produced and
released in the inflammatory processes of autoimmune diseases. In
our effort to better understand the significance of a T-cell
signature cytokine phenotype, our analysis of other related
publications indicated that either a Th1 or Th17 cytokine profile
in four different animal autoimmune models were specifically
induced and discussed for only that particular disease model.
However the meanings for therapeutic interventions or overall
significance in light of each other were not recognized,” stated
Dr. Zimmerman.
About LEAPS
L.E.A.P.S. is a patented, T-cell modulation, peptide epitope
delivery technology that enables CEL-SCI to design and synthesize
proprietary peptide immunogens. L.E.A.P.S. compounds consist of a
small T-cell binding peptide ligand linked with a
disease-associated peptide antigen. This platform technology has
been shown in several animal models to preferentially direct immune
response to a cellular (e.g. T-cell), humoral (antibody) or mixed
pathway. It has the potential to be utilized in diseases for which
antigenic epitope sequences have already been identified, such as:
a number of infectious diseases, some cancers, autoimmune diseases,
allergic asthma and allergy, and select CNS diseases (e.g.,
Alzheimer's).
About CEL-SCI Corporation
CEL-SCI’s work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. Its lead
investigational therapy Multikine (Leukocyte Interleukin,
Injection) is currently being studied in a pivotal Phase III
clinical trial against head and neck cancer. If the study endpoint,
which is a 10% improvement in overall survival of the subjects
treated with Multikine treatment regimen as compared to subjects
treated with current standard of care only is satisfied, the study
results will be used to support applications which will be
submitted to regulatory agencies in order to receive from these
agencies commercial marketing approvals for Multikine in major
markets around the world. Additional clinical indications for
Multikine which are being investigated include cervical dysplasia
in HIV/HPV co-infected women, and the treatment of peri-anal warts
in HIV/HPV co-infected men and women. A Phase I trial of the former
indication has been completed at the University of Maryland. The
latter indication is now in a Phase I trial in conjunction with the
U.S. Navy under a CRADA (Cooperative Research and Development
Agreement).
CEL-SCI is also developing its LEAPS technology for the
treatment of pandemic influenza and as a potential therapeutic
vaccine against rheumatoid arthritis. The Company has operations in
Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
When used in this report, the words "intends," "believes,"
"anticipated", “plans” and "expects" and similar expressions are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties which could cause actual
results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability
to duplicate the clinical results demonstrated in clinical studies,
timely development of any potential products that can be shown to
be safe and effective, receiving necessary regulatory approvals,
difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital and the risk
factors set forth from time to time in CEL-SCI Corporation's SEC
filings, including but not limited to its report on Form 10-K for
the year ended September 30, 2013. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024